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Abstract Approximately 10% of all familial cases of amyo-
trophic lateral sclerosis (fALS) are linked to mutations in the
SOD1 gene, which encodes the copper/zinc superoxide dismutase
(CuZnSOD). Recently, wild-type CuZnSOD was shown to
protect calcineurin, a calcium/calmodulin-regulated phosphopro-
tein phosphatase, from inactivation by reactive oxygen species.
We asked whether the protective effect of CuZnSOD on
calcineurin is affected by mutations associated with fALS. For
this, we monitored calcineurin activity in the presence of mutant
and wild-type SOD. We found that the degree of protection
against inactivation of calcineurin by different SOD mutants
correlates with the severity of the phenotype associated with the
different mutations, suggesting a potential role for calcineurin^
SOD1 interaction in the etiology of fALS. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Mutations in the SOD1 gene, which encodes the enzyme
copper/zinc superoxide dismutase, are associated with familial
amyotrophic lateral sclerosis (fALS), a fatal neurodegenera-
tive disorder a¡ecting spinal cord and brain motor neurons
[1]. It typically results in mortality within a few years after
diagnosis. The mechanisms by which these mutations lead to
the selective death of motor neurons are unknown. However,
there is evidence for gain of function mechanisms such as
enhanced peroxide or hydroxyl radical production [2], changes
in the protein structure [3], and alterations in the metal-bind-
ing properties [4]. Today, more than 70 di¡erent mutations of
the SOD1 gene are known ranging from mutations that are
associated with a mild, slowly progressive form of fALS to
mutations that cause a very rapid progression of the disease.
Recently, it was shown that SOD1 protects calcineurin, a
serine/threonine-speci¢c calcium/calmodulin-dependent phos-
phoprotein phosphatase, from inactivation by reactive oxygen
species [5]. Calcineurin has been implicated in a wide range of
diseases including ALS [6^9]. In addition, calcineurin is in-
volved in a variety of cellular responses to calcium-mobilizing
signals, including the control of ion channels, the release of
neurotransmitters, and gene transcription [10].
In spite of the impressive amount of data collected during
the last years, the primary molecular targets of the mutated
SOD1 in fALS are still unknown. In order to address our
hypothesis that calcineurin is one of the targets, we investi-
gated the ability of four di¡erent copper/zinc superoxide dis-
mutase (CuZnSOD) proteins, three mutant forms and the
wild-type (wt) enzyme, to protect calcineurin from oxidative
inactivation in vitro.
In this study, we report that the mutant SODs were signi¢-
cantly less protective against calcineurin inactivation, and that
the severity of the loss of protection seems to be related to the
severity of the respective form of fALS.
2. Materials and methods
2.1. Preparation of tissue extracts
100 ng^1 Wg puri¢ed bovine brain calcineurin (Sigma Aldrich, Dei-
senhofen, Germany) or 100 Wg homogenized tissue or cell extracts
were used for standard calcineurin phosphatase assays. 100 Wg cells
or tissue were homogenized exactly as described [11]. Partially puri¢ed
and redox-sensitive calcineurin was prepared by centrifugation of ho-
mogenates at 14 000 rpm at 4‡C for 10 min (Eppendorf centrifuge
5417R) and separation of the resulting supernatant on a 1.5U10 cm
Sephadex-G50 gel ¢ltration column as described [11,12].
2.2. Recombinant expression and puri¢cation of wt and mutated
CuZnSOD
CuZnSOD-pQE60 transformed Escherichia coli M15[pREP4] cells
were plated on Luria^Bertani (LB)/ampicillin (100 Wg/ml)/kanamycin
(25 Wg/ml) agar. Cultures were grown in 250 ml LB/ampicillin (100 Wg/
ml)/kanamycin (25 Wg/ml) until OD600 was 0.6. Constitutive leakage
expression of human CuZnSOD was fully prevented by the repressor
plasmid pREP4-lacI. Production of the human CuZnSOD fusion pro-
teins was induced by addition of IPTG (1 mM). After 2 h, the bac-
terial cells were harvested by centrifugation (4000Ug, 20 min), resus-
pended in 8 ml bu¡er A (20 mM Tris^HCl, pH 7.9, 5 mM imidazole,
500 mM NaCl) and homogenized by four freeze^thaw cycles and
sonication on ice (Bandelin sonoplus GM70, 300 W, 3U10 s). The
lysate was centrifuged (10 000Ug, 20 min) and incubated with 750 Wl
Ni-NTA-agarose for batch a⁄nity binding (1 h, 4 ‡C). The batch was
applied to a 30 ml chromatography column, washed with 15 ml bu¡er
A and subsequently with 8 ml bu¡er B (20 mM Tris^HCl, pH 7.9,
60 mM imidazole, 500 mM NaCl). C-terminal histidine-tagged CuZn-
SOD was eluted three times with 1.2 ml bu¡er C (10 mM Tris^HCl,
500 mM imidazole, 250 mM NaCl). Purity and identity of expression
products was veri¢ed by immunoblotting or N-terminal protein se-
quencing after separation of 20 Wl eluate in SDS^PAGE (discontinu-
ous 12.5% SDS^PAGE).
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2.3. Reactivation of CuZnSOD
Wt and mutant SODs were puri¢ed and demetalated by Ni-NTA-
a⁄nity chromatography using imidazole (500 mM) as an eluant. In
order to yield physiologically relevant active homodimeric CuZnSOD,
the Ni-NTA eluate was subjected to ultra¢ltration (3 kDa membrane
from Centrex UF 0.5, Schleicher and Schuell, Dassel, Germany). For
bu¡er changes, the samples were washed three times in refolding bu¡-
er (50 mM sodium citrate, pH 5.5, 1 mM dithiothreitol (DTT). After
addition of CuSO4 (200 WM) and ZnCl2 (200 WM), the protein solu-
tions were incubated at 8 ‡C or 37 ‡C for 7 days (250 Wg/ml protein).
2.4. SOD assay and activity staining
Enzymatic activity of the CuZnSOD proteins was either analyzed
by 10% native gel electrophoresis and activity staining with nitroblue
tetrazolium dye, or by a quantitative spectrophotometrical assay ac-
cording to published protocols [13,14]. Protein yields were determined
by the Bradford method (Protein assay kit, Bio-Rad, Hercules, CA,
USA). The concentration of puri¢ed CuZnSOD was determined spec-
trophotometrically using the extinction coe⁄cient O265 = 1.84U104
M31 cm31.
2.5. Atomic emission spectrometry
For atomic emission spectrometry (AES), SOD proteins were
washed ¢ve times in refolding bu¡er (Centrex UF 0.5, Schleicher
and Schuell, Dassel, Germany). 100 Wg protein in 1 ml were added
to 0.5 ml HNO3 and incubated at 95‡C for 30 min. After cooling to
room temperature, 10 ml H2O was added and the samples were an-
alyzed with a ICP-VISTA RL CCD simultaneous ICP-AES.
Phosphoserine phosphatase assay was performed as described pre-
viously [5,15]. In brief, 40 Wl recombinant or partially puri¢ed calci-
neurin was mixed with test bu¡er (40 mM Tris^HCl, pH 8, 0.1 M
KCl, 0.4 mg/ml BSA, 0.67 mM DTT, 0.67 WM calmodulin, 1 WM
FKBP and 0.5 WM okadaic acid for inhibition of phophotase A1
and A2). Calcium-induced redox inactivation of calcineurin was
started by addition of 20 Wl substrate bu¡er (0.67 mM CaCl2, ¢nal
concentration). At the indicated time points (2 min and 20 min),
substrate was added (7.7 WM 32P-phosphorylated RII-peptide) and
the reaction was incubated for 2 min at 30‡C. Assays were performed
in duplicate, repeated six times, and the inhibition of calcineurin ac-
tivity by addition of 1 WM FK506 or cyclosporine was used to verify
background activity for each reading point. The degree of protection
by CuZnSOD against redox inactivation of calcineurin was deter-
mined by the addition of recombinant human wt, mutated CuZnSOD
or of puri¢ed human erythrocyte CuZnSOD (200 ng or 800 ng, re-
spectively). After 2 min at 30‡C, the reaction was stopped with
100 mM potassium phosphate/5% TCA. The reaction mixture was
passed through a 0.5 ml ion-exchange column (Dowex; AG 50W-
X8, Bio-Rad) and the unbound phosphate eluted with 0.5 ml water.
The quantity of released phosphate was determined by scintillation
counting.
2.6. Non-radioactive calcineurin assay
5 Wl of protein extract was added to a 96-well plate containing 25 Wl
of 2U assay bu¡er (Calbiochem), 5 Wl okadaic acid (5 Wm), 200 Wg of
SOD proteins and water ad 40 Wl. Reaction was started by addition of
10 Wl of phosphopeptide substrate. After 20 min incubation at room
temperature, 50 Wl of Green solution (Calbiochem) was added to each
well and after additional 30 min, absorbance was read at 595 nm on a
plate reader (Biolumin 960, Molecular Dynamics).
3. Results
To test the hypothesis that calcineurin is a target of mu-
tated SOD1, we used recombinant wt enzyme and three var-
iants associated with distinct clinical phenotypes. The muta-
tions studied were associated with a rapidly progressive
(amino acid substitution A4V), a classic (G93A) or a benign
(D90A) course of ALS. In our expression, puri¢cation and
reconstitution system, the D90A exhibited 78.5% of the spe-
ci¢c activity, whereas the speci¢c enzymatic activity of the
G93A (22%) and A4V (13%) mutants CuZnSODs was pro-
foundly reduced (Fig. 1). Activity staining of native electro-
pherograms with NBT showed a corresponding pattern, with
wt SOD showing the highest activity followed by the D90A
mutant, whereas the activities of G93A and A4V mutants
were strongly reduced (Fig. 1, lower panel). In line with the
reduced zinc a⁄nity of the mutants described by others
[16,17], the metal content of the reactivated enzymes di¡ered
between the mutants (Fig. 1).
Incubation of calcineurin for 20 min at 30‡C under aerobic
conditions in the presence of calcium led to a rapid loss of
phosphoserine phosphatase activity to 5^8% of baseline activ-
ity (Fig. 2a). This inactivation was Ca2-dependent and as
e¡ective as speci¢c inhibition of calcineurin by FK506 (2.5%
baseline activity). Oxidative inactivation could be prevented
almost completely by addition of the Ca2 chelator EDTA,
verifying the Ca2 dependency of the oxidative inactivation of
calcineurin. Puri¢ed human erythrocyte CuZnSOD (1.7 U,
Sigma-Biochemicals) or human recombinant wt CuZnSOD
(200 ng, 1.7 U) preserved 58% of calcineurin baseline activity
in the presence of Ca2 and oxygen (Fig. 2b), which is in
keeping with recent ¢ndings by others [5]. Mutant hSODs
(200 ng) were signi¢cantly less protective against calcineurin
inactivation (Fig. 2b, light bars), and the degree of loss of
protection was related to the severity of the respective form
of fALS. The D90A mutation, found in a more benign form
of fALS, which only gives rise to ALS in homozygous indi-
viduals, conveyed the most protection of calcineurin activity
of the mutant SODs studied. The A4V mutant protein, which
is associated with severely progressive fALS, was the least
e¡ective. The CuZnSOD bearing the G93A mutation, which
is associated with standard/classic fALS, preserved only 22%
of calcineurin activity, a loss of over 60% of the protection
confered by wt SOD. This e¡ect was not due to reduced SOD
activity of the mutant SODs compared to wt: when the
amounts of wt or mutant SOD were quadrupled (800 ng),
the loss of protection of calcineurin activity was magni¢ed,
rather than reduced, for the fALS SOD mutants (Fig. 2b,
dark bars), however, the di¡erences in protection between
200 and 800 ng were not signi¢cant as tested by analysis of
variance. While wt SOD maintained its protective e¡ect on
calcineurin activity and co-incubation of calcineurin with the
SODs associated with benign (D9OA) and classic (G93A)
fALS only showed a slight reduction compared to 200 ng of
SOD, the SOD associated with the most severe form of fALS
(A4V) resulted in a loss of 92% of calcineurin activity, mean-
ing that over 80% of the protection of wt hSOD were lost due
to this mutation. Repetition of this experiment with similar
Fig. 1. Characterization of the SOD1 proteins. The recombinant
SOD1 proteins are characterized by a reduced activity and a re-
duced zinc content. Lower panel: Activity staining of recombinant
SOD1 proteins. Activity was measured after 168 h of reactivation
by a quantitative spectrophotometrical assay. Activity measurement,
substrate gels and ion-content measurement were performed as de-
scribed in Section 2. n = 6.
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amounts of units of each mutant (1.7 U) gave essentially the
same results (data not shown).
To address the observation that increased amounts of mu-
tant SOD compounded the loss of calcineurin activity, we
tested a mixture of wt and G93A mutant (400 ng each). Cal-
cineurin activity was measured by the dephosphorylation of
the RII peptide as described in Section 2.
As shown in Fig. 3, a mixture of wt and G93A, as well as
A4V mutations, showed an intermediate degree of protection.
Our results thus demonstrate that mutant SODs can reduce
the protection conferred by wt SOD. This observation sup-
ports the hypothesis that the SOD1 mutations found in fALS
result in a negative gain of function, in this case in a reduction
of the protection of calcineurin by wt SOD.
4. Discussion
How the di¡erent mutations in the ubiquitously expressed
enzyme SOD cause the highly speci¢c neuropathological phe-
notype associated with fALS remains elusive. Direct damage
of cellular components by reactive oxygen species, but not
superoxide, remains the predominant hypothesis. However,
recent results argue against a simple accumulation of free
radical or other damage in neuronal degenerations of various
types, and rather suggest a ‘one-hit’ biochemical model in
which the mutations impose a ‘mutant steady state’ on the
a¡ected neuron, and single events unrelated to the mutation
randomly initiate the cell death [18]. The question of how this
mutant steady state is induced remains unsolved, and the bio-
chemical or genetic parameters are unde¢ned.
Calcineurin is a calcium-dependent phosphoprotein phos-
phatase regulated by calmodulin. It has been implicated in a
variety of cellular responses to calcium-mobilizing signals, for
example the regulation of neuronal excitability by controlling
the activity of ion channels, the release of neurotransmitters,
synaptic plasticity, and gene transcription [10]. As calcineurin
Fig. 2. Mutated CuZnSOD is less e⁄cient in protecting calcineurin activity. a: Fast inactivation of calcineurin in the presence of calcium under
aerobic conditions (left). CN activity was measured after 2 and after 20 min. Without early addition of calcium (upper dotted line), the CN
activity remains stable until the start of the calcineurin measurement (second arrow), whereas after addition of calcium, the activity declines
rapidly within 20 min. Addition of the chelator EDTA or co-incubation with CuZnSOD reduce the inactivation by oxygen (representative ex-
periment, right), whereas addition of FK506, a calcineurin inhibitor, abolishes its activity. b: Calcineurin activity can be preserved by addition
of erythrocyte (ery) SOD or recombinant human (hr) SOD. Recombinant mutant SODs associated with fALS are less protective. Addition of
quadruple amounts of wt or mutant SODs (black bars) reduces the protective ability of the mutants even more. Calcineurin activity was
assessed as described in Section 2. Values are given as mean þ standard deviation. n = 6; *P6 0.05, signi¢cantly di¡erent from wt SOD by Stu-
dent’s t-test; **P6 0.01, signi¢cantly di¡erent from wt SOD by Student’s t-test.
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comprises more than 1% of the total protein in the nervous
system [19] and its activity can be protected by CuZnSOD [5],
which itself accounts for 2% of brain protein, SOD and calci-
neurin are both among the most abundant proteins in neuro-
nal cells. Therefore, calcineurin would be an ideal candidate
for a proposed in£uence of superoxide dismutase mutations
on signal transduction pathways leading to a mutant steady
state ¢nally resulting in neurodegeneration.
In this study, we report that mutated SODs loose their
capacity to protect calcineurin from oxidative inactivation,
as shown herein for three di¡erent mutations associated
with di¡erent clinical phenotypes. In addition, the extent of
loss of protection was related to the severity of the associated
clinical phenotype. The SOD mutant showing the least pro-
tective e¡ect (A4V) is associated with the most aggressive
form of fALS, whereas an intermediate protective mutant
(G93A) corresponded to an intermediate fALS progression
rate and a mutation (D90A) linked to relatively benign form
of fALS retained the highest protective ability of the three
tested mutants. These results are in keeping with the observa-
tions of a reduced calcineurin activity in human neuroblasto-
ma cells transfected with mutated SOD1 and in the forebrains
of fALS-transgenic mice [9].
Moreover, when the amount of SOD protein was qua-
drupled in the assay, the wt maintained its protective ability,
whereas the mutants showed an even more prominent loss of
calcineurin protection. A mixture of both mutant and wt pro-
teins showed an intermediate rate of protection. These results
indicate that either the presence of the wt CuZnSOD protein,
and not simply the presence of SOD activity, is needed for the
protection of calcineurin from oxidative inactivation, or that
the increased inactivation of calcineurin is mediated by mu-
tated SOD-generated oxidative species di¡erent from super-
oxide, a hypothesis that has already been suggested by others
[10,20]. Both possibilities would be in accordance with the
notion that overexpression of wt SOD together with fALS-
associated SOD is not protective [21], an observation that is
strengthened by the fact that a mixture of wt and mutant
SODs only confers an intermediate rate of protection. The
partial protective e¡ect of wt SOD when mixed with mutant
SOD may be explained by the necessity of SOD to bind to
calcineurin to exert its protective e¡ect. Wt and mutant SODs
therefore would compete for binding to calcineurin, so that
part of the calcineurin molecules still could be protected by wt
SOD.
It has to be noted, however, that the recombinant reconsti-
tuted SOD1 proteins used in this study show an abnormal
zinc content, and therefore may not be completely refolded.
A reduced a⁄nity of SOD1 mutants for zinc is an observation
that has already been made by others [16,17], and therefore a
reduced zinc content of the recombinant proteins is not sur-
prising. At the moment, we cannot evaluate to what extent
this fact in£uences the observed results. However, our wt
SOD1 gives exactly the same rate of protection as SOD1
puri¢ed from erythrocytes, and the D90A mutation, which
shows a greatly reduced zinc content, shows a greater rate
of protection than does the A4V mutant, whose zinc content
is closer to that of the wt enzyme. This suggests that zinc
content and protective ability are not directly related.
Independent of its relevance for ALS, our data give addi-
tional information that calcineurin is regulated not only by
calcium, but also on the redox level. As other possible regu-
latory mechanisms such as cleavage of the autoinhibitory do-
main or inactivation by an endogenous FK506-analog have
also been discussed, the picture of calcineurin regulation be-
comes increasingly complex.
Since the calcineurin inactivation is dependent on the pres-
ence of calcium, motoneurons, which are subject to gluta-
mate-receptor-mediated Ca2 in£uxes, may be especially at
risk for calcineurin inactivation. Moreover, calcineurin is re-
sponsible for the desensitization of NMDA receptor channels
by dephosphorylating them. In light of our results, a reduc-
tion of calcineurin activity by mutant SODs would therefore
lead to prolonged NMDA receptor-channel openings, and
therefore to an increased Ca2 uptake, aggravating the situa-
tion even more. This would explain why glutamate potentiates
the toxicity of mutant SOD1 in motor neurons [22]. As an
inactivation of calcineurin has been shown early in cell death
through apoptosis in some neuronal cell culture systems, and
a higher Ca content in cells expressing mutant SODs or in
mutant SOD1 transgenic mice has been observed [23^25], a
dysregulation of the cellular calcium levels via calcineurin in-
hibition could explain the above-mentioned mutant steady
state which renders motoneurons more susceptible to single
random events that ¢nally initiate cell death.
Our data show that the degree of calcineurin impairment
depends on the type of mutation in CuZnSOD and corre-
sponds to the severity of the disease. This suggests that altered
calcineurin activity is at least partially involved in the disease
progression in fALS. Protection of calcineurin against oxida-
tive inactivation may therefore be a therapeutic approach in
the treatment of ALS.
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